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Abstract Calprotectin (Cal) concentration is elevated in
acute inflammatory reactions and its increase in the plasma
suggests a diagnostic potential for Cal assay. This study
aimed (a) to evaluate the Cal plasma levels in patients suf-
fering from acute pancreatitis (AP) and (b) to assess whether
early assay of Cal plasma levels can be helpful in assessment
of the severity of AP. Forty-six consecutive patients, median
age 45 years, suffering from a first attack of AP were re-
cruited at two medical centers. Data collected on admission
included age, sex, delay between pain onset and admission,
and Glasgow score. A severe outcome was defined accord-
ing to the Atlanta criteria. AP was defined as edematous or
necrotic according to the CT findings. Plasma Cal and serum
C reactive protein (CRP) were assayed in all patients within
the first 24 hr after hospitalization. Sixty subjects suffering
from blood hypertension were recruited as controls. Plasma
Cal was measured by a commercial ELISA system. In all AP
patients and in none of the controls, plasma Cal concentra-
tion was higher than the normal limit. Cal values in AP pa-
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tients were significantly higher than in controls (P < 0.0001).
There was not a statistically significant difference in Cal val-
ues between patients with severe and patients with mild AP.
Plasma Cal values did not differ in necrotizing and edema-
tous AP. During the follow-up plasma Cal was reassayed in
six of the patients with abdominal fluid collection and the
values were higher in the two patients with infected necrosis.
We conclude that plasma Cal is elevated in patients with AP
but it is not a useful marker for early prediction of pancreati-
tis severity. Further studies could evaluate its usefulness in
pancreatic infected necrosis.
Keywords Calprotectin . Acute pancreatits . Pancreatic
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Introduction
Calprotectin (Cal) is a calcium binding protein belonging to
the S-100 protein family and derived predominantly from
neutrophils and monocytes [1, 2]. Various biological func-
tions have been ascribed to Cal, including regulation in the
inflammatory process [3] and antimicrobial activity [4]. Cal
concentration is elevated in acute inflammatory reactions,
and in some instances a correlation between Cal and other
inflammation paramenters such as C reactive protein (CRP),
erythrocyte sedimentation rate, and neutrophil granulocyte
count has been shown [5]. As Cal is found in all tissues of
the human body, its assessment in several fluids could distin-
guish between normal and pathological conditions [2]. For
instance, an elevated Cal concentration in stools is consid-
ered a marker of intestinal neoplasias [6] or inflammatory
bowel diseases [7] and helps to distinguish between organic
causes of chronic diarrhea and irritable bowel syndrome [8].
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An increased concentration of Cal in the plasma has been
found in several organic diseases and suggests a diagnos-
tic potential for Cal assay [2]. Despite these very promising
data, no studies on the plasma Cal concentration in patients
with acute pancreatits (AP) have been performed to date.
Aims of the present study were (a) to evaluate Cal plasma
levels in patients suffering from AP and (b) to investigate
whether early assay of Cal plasma levels could be helpful in
assessment of the severity of AP.
Patients and methods
Forty-six consecutive patients (25 males), median age 45
years (range, 19–75 years), suffering from a first attack of AP
were recruited at two medical centers, between January and
December 2002. The diagnosis was based on the association
of clinical symptoms, serum lipase and amylase increase,
and characteristic computed tomographic (CT) findings. Pa-
tients with prior episodes of unexplained abdominal pain or
with signs of chronic pancreatitis were excluded. Thirty-four
patients had biliary AP, diagnosed on ultrasound or CT ex-
aminations; five had alcohol-induced AP, as they reported
a daily intake of >100 g pure alcohol and an alcohol ex-
cess immediately before the acute attack; and in seven cases
the etiology remained unknown (idiopathic AP). Data col-
lected on admission included age, sex, delay from pain onset
to admission, and Glasgow score [9]. A severe outcome was
defined according to the Atlanta criteria [10]. AP was defined
as edematous or necrotic according to the contrast-enhanced
CT findings. Serum amylase and lipase and plasma Cal were
assayed in all patients within the first 24 hr after hospitali-
sation; all the biochemical markers included in the Glasgow
score and the CRP concentration were analyzed on the same
blood sample.
Sixty subjects suffering from blood hypertension, sex and
age matched with the study group, without inflammatory
diseases or a history of acohol abuse, and with normal serum
amylase values, were recruited as controls for plasma Cal
values.
All subjects gave their informed consent to all procedures
described in this study. The study protocol was approved by
the Ethics Committee of the University Hospital of Palermo.
Plasma calprotectin determination
Blood samples were drawn into EDTA tubes and centrifuged
at 2000 rpm for 15 min. Laboratory personnel unaware of
the clinical diagnoses or details of the patients’ clinical
histories assayed plasma calprotectin. The concentrations
were measured using a commercial ELISA system (Calprest;
Eurospital, Trieste, Italy) based on polyclonal antibodies
against calprotectin. Two 100-µl plasma aliquots from a sin-
gle sample from each participant were assayed, and the mean
of the two measurements was recorded. Threshold values
supplied by the manufacturer (normal values, 0.3–1.6 µg/ml)
were considered for statistical analysis. The intra-assay co-
efficient of variation (CV) for plasma Cal was 3.8% at a
mean (SD) of 1.1 (0.2) (n = 20), and the interassay CV was
8%. The physicians who made the final evaluation of the
AP severity were unaware of the Cal results throughout the
study.
Statistical analysis
For the intergroup Cal concentration comparison, we used
Mann-Whitney U test or Student’s t test according to whether
there was a non-Gaussian or Gaussian distribution of the
data. The Spearman r correlation coefficient was used to
correlate plasma Cal concentration with CRP and Glasgow
score values.
Results
In all AP patients plasma Cal concentration was higher
than the normal limit: the values ranged between 1.7 and
6.3 µg/ml. On the contary, none of the control subjects had
values above the reference limit (Fig. 1). Plasma Cal val-
ues in AP patients were significantly higher than in controls:
mean values (SD) were 5.3 (1.9) µg/ml in AP and 1.0 (0.3)
µg/ml in controls (P < 0.0001). In patients with AP there
was a trend toward higher plasma Cal values in cases with
alcoholic etiology than in those due to gallstones (mean val-
ues ± SD, 5.6 + 1.2 versus 5.1 ± 1.0 µg/ml; difference not
statistically significant).
According to the Atlanta criteria for AP severity, 12 pa-
tients (26%) had severe AP and 34 (74%) had mild AP.
Figure 2 shows the individual and median plasma Cal val-
ues in patients with severe and mild AP; there was a trend
toward higher plasma Cal values in patients with severe pan-
creatitis, but the difference was not statistically significant
in comparison with values observed in mild AP. Serum CRP
concentration was higher in patients with severe AP than in
those with a mild form, and this difference was statistically
significant: mean (SD) values were 18.5 (4.3) mg/L in severe
AP and 3.9 (2.9) mg/dl in mild forms (P < 0.0001). Also,
the Glasgow score was significantly higher in patients with
severe than in those with mild AP (P = 0.04). No statistically
significant correlation was found between plasma Cal values
and CRP concentration or Glasgow score.
Contrast-enhanced CT revealed necrotizing pancreatitis
in 11 patients and edematous AP in the others; plasma Cal
values, although higher in the subjects with necrosis, did not
differ according to the presence or absence of the necro-
sis. Further CT evaluation showed the development of a
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Fig. 1 Individual and mean (Barr) values of plasma calprotectin in patients with acute pancreatitis and in controls
Fig. 2 Individual and mean (Barr) values of plasma calprotectin in patients with acute pancreatitis, divided according to the Atlanta criteria for
severity of pancreatitis
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pancreatic pseudocyst in five patients; plasma Cal values
at hospitalisation did not differ between patients who devel-
oped a pseudocyst in comparison with all other AP patients.
During the hospital stay, pancreatic infected necrosis was
found in two patients; at the moment of the hospitalization,
the plasma Cal values of these two patients did not differ from
those of all other AP patients. However, between the 6th and
the10th days of hospitalization, plasma Cal was reassayed
in six of the patients with abdominal fluid collection and
suspected infected necrosis, including the two subjects who
really had infected necrosis. The latter subjects had plasma
Cal values higher than those of the others: 6.1 and 7.2 mg/dl
in the patients with infected necrosis versus 3.2, 2.3, 1.8,
and 1.8 mg/dl in the patients with fluid collection without
infection.
Only two patients underwent surgical treatment, both for
infected necrosis (necrosectomy with a left sided resection);
one of them died in the first week after surgery.
Discussion
Plasma Cal is an interesting marker of inflammation. Previ-
ous studies demonstrated its usefulness in active rheumatic
disease [5, 11], cystic fibrosis [12], pulmonary infections
[13], and several other diseases [2]. In all cases the differ-
ences between normal and pathological levels suggested a di-
agnostic potential for Cal assay. Although Cal is mainly pro-
duced by neutrophils and monocytes, it is found in cells in all
part of the body and its presence has also been demonstrated
in pancreatic cells [14]. Despite these promising prospec-
tives, no previous studies have evaluated the usefulnes of
plasma Cal assay in patients with AP.
Our results demonstrate that plasma Cal is elevated in all
patients with AP and in none of the controls; however, as we
recruited control subjects without signs of acute inflamma-
tion, the high specificity of Cal in identifying AP patients
cannot be considered a “real” result, and, on the other hand,
serum amylase and lipase assays are considered sufficiently
specific to confirm the clinical suspicion of AP. A more re-
alistic goal in AP patients is the prediction of severity [15,
16]; in fact, early assessment of severity in AP can permit
the selection of those patients who will benefit from a more
intensive and early treatment with antibiotics [17] or an-
tiprotease drugs [18], although this last point is still being
debated [19, 20]. Unfortunately, in this respect, plasma Cal
assay did not offer any advantage. Although there was a trend
for higher Cal values in severe versus mild AP and in necro-
tizing versus edematous AP, the overlap of values between
the groups did not permit any prediction of the course of
the disease. On the contrary, serum CRP concentration con-
firmed its usefulness in distinguishing between severe and
mild forms of AP [21, 22]. Obviously, it remains to verify
whether a later assay of plasma Cal, or its monitoring during
the hospital stay, could indicate the severity of AP, but even
if so, a late prediction of AP severity is less important. How-
ever, the last result of the present study could be reevaluated
in future researches: the use of plasma Cal as a marker of
pancreatic infected necrosis. In fact, when plasma Cal was
assayed in six patients with suspected infected necrosis, the
highest values were recorded in the two patients who really
suffered from infected necrosis.
In conclusion, we have shown that plasma Cal is elevated
in patients with AP but it is not a useful marker for early pre-
diction of the severity of pancreatitis. Further studies could
evaluate its usefulness in patients who will develop infection
of pancreatic necrosis, which still remains an unforeseeable
event in the course of the disease.
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